Gemcitabine Alone versus combination of Gemcitabine and Cisplatin for the Treatment of Patients with Locally Advanced and/or Metastatic Pancreatic Carcinoma: A Retrospective Analysis of multicenter study

Basit Öğe Kaydı
dc.authoridbenekli, mustafa/0000-0003-3184-4946
dc.authoridKos, Fahriye Tugba/0000-0002-6980-4942
dc.authoridElkıran, Emin Tamer/0000-0001-6681-7249
dc.authoridGöksel, Gamze/0000-0002-7991-0036
dc.authoridAlgın, Efnan/0000-0002-8917-9267
dc.authoridKaplan, Muhammet Ali/0000-0003-0882-0524
dc.authorwosidbenekli, mustafa/AAE-4555-2020
dc.authorwosidKos, Fahriye Tugba/D-8952-2016
dc.authorwosidElkıran, Emin Tamer/ABI-8192-2020
dc.authorwosidGeredeli, Caglayan/AAN-4122-2020
dc.authorwosidGumus, Mahmut/HTO-4176-2023
dc.authorwosidKucukoner, Mehmet/E-1162-2013
dc.authorwosidcolak, dilsen/GRY-5456-2022
dc.contributor.authorInal, A.
dc.contributor.authorKos, F. T.
dc.contributor.authorAlgin, E.
dc.contributor.authorYildiz, R.
dc.contributor.authorDikiltas, M.
dc.contributor.authorUnek, I. T.
dc.contributor.authorColak, D.
dc.date.accessioned2024-08-04T20:36:00Z
dc.date.available2024-08-04T20:36:00Z
dc.date.issued2012
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe majority of patients with pancreatic cancer is of advanced disease. Several randomized Phase II and III trials suggest that the combination of gemcitabine and cisplatin (GemCis) response rates were higher than Gemcitabine (Gem) alone, however the trials were not enough powered to indicate a statistically significant prolongation of survival in patients with advanced pancreatic adenocarcinoma. The aim of this retrospective multicenter study is to evaluated the efficiency of Gem alone versus GemCis in patients with locally advanced and/or metastatic pancreatic adenocarcinoma. A total of 406 patients, from fourteen centers were evaluated retrospectively. All patients received Gem or GemCis as first-line treatment between September 2005 to March 2011. Primary end of this study were to evaluate the toxicity, clinical response rate, progression-free survival (PFS) and overall survival (OS) between the arms. There were 156 patients (M: 98, F: 58) in Gem arm and 250 patients (M: 175, F: 75) in the combination arm. Gemcitabin arm patients older than the combination arm ( median 63 vs 57.5, p=0.001). In patients with the combination arm had a higher dose reduction (25.2% vs 11.3%, p=0.001) and dose delay (34% vs 16.8%, p=0.001). Among patients with the combination and Gemcitabin arm gender, diabetes mellitus, performance status, cholestasis, grade, stage did not have a statistically difference (p>0.05). Clinical response rate to the combination arm was higher than the Gem arm (69.0% vs 49.7%, p=0.001). PFS was more favorable in the GemCis arm than Gem alone, but the difference did not attain statistical significance (8.9 vs 6.0, p=0.08). OS was not significantly superior in the GemCis arm (12.0 vs 10.2, p>0.05). Grade III-IV hematologic and nonhematologic toxicity were higher in the combination arm. PFS was more favorable in the GemCis arm than Gem alone, but the difference did not attain statistical significance. OS was not significantly superior in the GemCis arm.en_US
dc.identifier.doi10.4149/neo_2012_038
dc.identifier.endpage301en_US
dc.identifier.issn0028-2685
dc.identifier.issn1338-4317
dc.identifier.issue3en_US
dc.identifier.pmid22329849en_US
dc.identifier.scopus2-s2.0-84863844209en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage297en_US
dc.identifier.urihttps://doi.org/10.4149/neo_2012_038
dc.identifier.urihttps://hdl.handle.net/11616/95720
dc.identifier.volume59en_US
dc.identifier.wosWOS:000301966700008en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAepress Sroen_US
dc.relation.ispartofNeoplasmaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectadvanced pancreatic canceren_US
dc.subjectfirst-line chemotherapyen_US
dc.subjectgemcitabineen_US
dc.subjectcisplatinen_US
dc.titleGemcitabine Alone versus combination of Gemcitabine and Cisplatin for the Treatment of Patients with Locally Advanced and/or Metastatic Pancreatic Carcinoma: A Retrospective Analysis of multicenter studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu